| Title |
Elevated Syndecan-1 levels in the sera of patients with breast cancer correlate with tumor size
|
|---|---|
| Published in |
Breast Cancer, April 2017
|
| DOI | 10.1007/s12282-017-0773-0 |
| Pubmed ID | |
| Authors |
Zahra Malek-Hosseini, Sina Jelodar, Abdolrasoul Talei, Abbas Ghaderi, Mehrnoosh Doroudchi |
| Abstract |
Breast cancer is the leading type of cancer in Iranian women and affects them at least one decade younger than their counterparts in developed countries. Breast tumor progression and metastasis is accompanied by a decrease in the membranous expression of Syndecan-1 and an increase in its shedding. We measured the level of soluble Syndecan-1 in the sera of Iranian patients with breast cancer. The study population included 61 chemotherapy-naïve breast cancer patients and 30 age/sex-matched healthy individuals. Blood was collected by venipuncture method and serum was separated, aliquoted and kept at -40 °C until used. A commercial ELISA was used to detect Syndecan-1 levels in the sera. Soluble Syndecan-1 levels were increased in the sera of patients with breast cancer compared to healthy controls (87.89 ± 89.29 vs. 47.57 ± 46.46 ng/ml, p = 0.005). There was a positive correlation between soluble Syndecan-1 levels and tumor size (p = 0.017). The serum level of Syndecan-1 in patients without calcification showed a trend of increase compared to that of patients with calcification (108.80 ± 101.76 vs. 59.82 ± 57.13 ng/ml). The positive correlation between soluble Syndecan-1 levels and tumor size in the present study highlights the importance of different varieties (cell-bound and soluble) of this molecule in the breast tumor progression and their significance as tumor biomarkers. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 23 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 23 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 5 | 22% |
| Student > Ph. D. Student | 4 | 17% |
| Other | 2 | 9% |
| Student > Master | 2 | 9% |
| Researcher | 2 | 9% |
| Other | 2 | 9% |
| Unknown | 6 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 5 | 22% |
| Biochemistry, Genetics and Molecular Biology | 4 | 17% |
| Immunology and Microbiology | 2 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 4% |
| Veterinary Science and Veterinary Medicine | 1 | 4% |
| Other | 3 | 13% |
| Unknown | 7 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 April 2017.
All research outputs
#21,476,880
of 23,975,976 outputs
Outputs from Breast Cancer
#458
of 614 outputs
Outputs of similar age
#274,386
of 312,579 outputs
Outputs of similar age from Breast Cancer
#12
of 17 outputs
Altmetric has tracked 23,975,976 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 614 research outputs from this source. They receive a mean Attention Score of 4.4. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 312,579 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.